ANVS Annovis Bio
- 6.650
- -0.640-8.78%
Annovis Bio News
Annovis Announces New Publication in a Peer-Reviewed Journal
Tue, 21 May 2024MALVERN, Pa., May 21, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for neur
Amgen's (AMGN) Tarlatamab Receives FDA Approval for SCLC
Biocryst Pharmaceuticals, T2 Biosystems, Annovis Bio Among Healthcare Movers
Buy Rating Maintained for Annovis Bio Ahead of Key Parkinson's Drug Trial Results
10 Health Care Stocks With Whale Alerts In Today's Session
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Stocks With More Than 10% Short Interest - Finviz Screener
Annovis Bio Shares Are Trading Higher After the Company Reported Better-than-expected Q1 GAAP EPS Results.
Annovis Bio Shares Are Trading Higher After the Company Reported Better-than-expected Q1 GAAP EPS Results.
Annovis Bio Is Maintained at Buy by HC Wainwright & Co.
Annovis Bio Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. : The Annovis Bio (ANVS.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $30.00 to $23.00.
HC Wainwright & Co. : The Annovis Bio (ANVS.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $30.00 to $23.00.
HC Wainwright & Co. Maintains Buy on Annovis Bio, Lowers Price Target to $23
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Annovis Bio (NYSE:ANVS) with a Buy and lowers the price target from $30 to $23.
Annovis Bio Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/13/2024 277.67% HC Wainwright & Co. $30 → $23 Maintains Buy 04/30/2024 326.93% Canaccord Genuity $36 →
Annovis Bio's Cash And Cash Equivalents Totaled $3.1M As Of March 31, 2024, Will Fund Its Operations Into The Fourth Quarter Of 2024
Annovis Bio's Cash And Cash Equivalents Totaled $3.1M As Of March 31, 2024, Will Fund Its Operations Into The Fourth Quarter Of 2024
Annovis Bio Q1 2024 GAAP EPS $(0.72) Beats $(0.86) Estimate
Annovis Bio Q1 2024 GAAP EPS $(0.72) Beats $(0.86) Estimate
Press Release: Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results
Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results MALVERN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a
Buy Rating Reaffirmed for Annovis Bio Amid Positive Prospects for Parkinson's Treatment
Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results
Mon, 13 May 2024MALVERN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for neur
Annovis Bio | 10-Q: Quarterly report
Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson's Disease
Thu, 09 May 2024MALVERN, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for neur
Annovis Bio Issues Key Update on Corporate Progress
Annovis Bio CEO Outlines Next Steps in Alzheimer's Research After Mixed Phase II/III Trial Results
Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, announced that Maria Maccecchini, Founder,
Analysis
Price Target
No Data
